Condition: Prostate Cancer · Sponsor: Mark Garzotto, MD
Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one high-risk criteria.
This description comes directly from the study's public registry record.
Wesley Stoller, MA · 5032208262 · stoller@ohsu.edu
Mark Garzotto, MD · 5032208262 · mark.garzotto@va.gov
Always discuss trial participation with your own doctor first.
| VA Portland Healthcare System | Portland, Oregon, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03753243